A lack of evidence is behind the NHS' decision to withhold a breakthrough prostate cancer drug from patients who have already been treated using another new generation drug, Nice said.
A spokeswoman for Nice said the committee were unable to "draw any conclusions" about what would happen if "milestone" enzalutamide was used by prostate cancer sufferers who had also taken abiraterone.
In the trial data provided by the manufacturer of enzalutamide none of the patients had received previous treatment with abiraterone, therefore the committee was not able to draw any conclusions about the effectiveness of enzalutamide after previous abiraterone treatment, and this is reflected in the recommendations.
We would welcome any additional data the manufacturer of enzalutamide can provide.
More top news
Should the motion go in favour of the anti-hunting lobby, the National Trust’s board will have to decide whether to adopt the ban.
Eight of the top 20 airports increased their charges in 2017, while five airports raised fees for dropping off passengers.
Felipe’s intervention, the second during the constitutional crisis, came as Madrid plans to impose direct rule on Catalonia.